New drug for blood cancers now in five phase II clinical trials
Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.
The drug is a small molecule inhibitor that suppresses the activity of a signaling pathway believed to contribute to a variety of blood cancers' eventual resistance to standard chemotherapy treatments.
More specifically, preclinical research, funded in part by the California Institute for Regenerative Medicine (CIRM), has shown that the drug coaxes ...



